Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

INCY

Incyte (INCY)

Incyte Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:INCY
DatumZeitQuelleÜberschriftSymbolFirma
20/06/202522h30Business WireUpdate on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic DermatitisNASDAQ:INCYIncyte Corporation
19/06/202511h28Business WireIncyte annonce l’autorisation de Monjuvi® (tafasitamab-cxix) par la FDA en combinaison avec rituximab et lénalidomide pour les patients souffrant de lymphome folliculaire en rechute ou réfractaireNASDAQ:INCYIncyte Corporation
19/06/202511h24Business WireIncyte gibt FDA-Zulassung für Monjuvi® (Tafasitamab-cxix) in Kombination mit Rituximab und Lenalidomid für Patienten mit rezidiviertem oder refraktärem follikulärem Lymphom bekanntNASDAQ:INCYIncyte Corporation
18/06/202522h02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INCYIncyte Corporation
18/06/202522h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INCYIncyte Corporation
18/06/202521h39Business WireIncyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular LymphomaNASDAQ:INCYIncyte Corporation
15/06/202523h20Business WirePrésentation à l'EHA2025 de données de dernière minute positives pour INCA033989, la thérapie d'Incyte première de sa catégorie ciblant la mutCALR dans le traitement de la thrombocythémie essentielleNASDAQ:INCYIncyte Corporation
15/06/202523h20Business WirePositive aktuelle Daten zu Incytes erstem mutCALR-gerichteten Medikament INCA033989 bei essenzieller Thrombozythämie auf der EHA2025 vorgestelltNASDAQ:INCYIncyte Corporation
15/06/202510h00Business WireQIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)NASDAQ:INCYIncyte Corporation
15/06/202509h15Business WirePositive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025NASDAQ:INCYIncyte Corporation
13/06/202511h15Business WireLes données de phase 3 concernant le retifanlimab (Zynyz®) d’Incyte chez les patients atteints d’un carcinome épidermoïde du canal anal (SCAC) ont été publiées dans The LancetNASDAQ:INCYIncyte Corporation
13/06/202511h15Business WirePhase-3-Daten für Retifanlimab (Zynyz®) von Incyte bei Patienten mit Plattenepithel-Analkarzinom (SCAC) werden in The Lancet veröffentlichtNASDAQ:INCYIncyte Corporation
13/06/202500h45Business WirePhase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The LancetNASDAQ:INCYIncyte Corporation
12/06/202522h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
12/06/202522h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
12/06/202522h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
12/06/202522h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
12/06/202522h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
12/06/202522h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
12/06/202522h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
11/06/202517h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
06/06/202522h30Business WireIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
05/06/202522h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
04/06/202518h06Business WireIncyte kündigt mehrere Präsentationen an, darunter neue aktuelle Daten zu seinem mutCALR-gerichteten monoklonalen Antikörper (INCA033989), die zur Präsentation auf der EHA 2025 angenommen wurdenNASDAQ:INCYIncyte Corporation
04/06/202517h59Business WireIncyte annonce plusieurs présentations, y compris des données de dernière minute pour son anticorps monoclonal ciblant mutCALR (INCA033989), accepté pour présentation à l'EHA 2025NASDAQ:INCYIncyte Corporation
03/06/202522h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
03/06/202522h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
03/06/202517h06IH Market NewsIncyte Shares Jump After EHA Conference Accepts Key Research PresentationsNASDAQ:INCYIncyte Corporation
03/06/202516h30Business WireIncyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025NASDAQ:INCYIncyte Corporation
02/06/202522h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
 Showing the most relevant articles for your search:NASDAQ:INCY